The safety of dopamine agonists in the treatment of Parkinson's disease

Author： Bonuccelli Ubaldo   Ceravolo Roberto  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.7, Iss.2, 2008-03, pp. : 111-127

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tolerability and Safety of Ropinirole versus Other Dopamine Agonists and Levodopa in the Treatment of Parkinson's Disease: Meta-Analysis of Randomized Controlled Trials

By Kulisevsky Jaime   Pagonabarraga Javier  

Drug Safety, Vol. 33, Iss. 2, 2010-02 ,pp. : 147-161

Adis International

Access to resources Recommend Favorite

Dopamine agonists in Parkinson’s disease

By Tintner Ron   Jankovic Joseph  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 11, 2003-11 ,pp. : 1803-1820

Informa Healthcare

Access to resources Recommend Favorite

The Role of Dopamine Agonists in the Treatment of Depression in Patients with Parkinson's Disease: A Systematic Review

By Leentjens Albert F.G.  

Drugs, Vol. 71, Iss. 3, 2011-02 ,pp. : 273-286

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Dopamine Agonists in the Treatment of Parkinson's Disease in Japan

By Shimbo T.  

PharmacoEconomics, Vol. 19, Iss. 8, 2001-01 ,pp. : 875-886

Adis International

Access to resources Recommend Favorite

Dopamine D3 Agonists in the Treatment of Parkinson&aposs Disease

By  

Current Topics in Medicinal Chemistry, Vol. 15, Iss. 10, 2015-05 ,pp. : 908-926

Bentham Science Publishers

Access to resources Recommend Favorite